查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1577094

至 2030 年肌萎缩侧索硬化症 (ALS) 药物市场预测：按药物类型、作用机制、给药途径、阶段、应用、最终用户和地区进行的全球分析

Amyotrophic Lateral Sclerosis Therapeutics Market Forecasts to 2030 - Global Analysis By Drug Type, Action Mechanism, Route Of Administration, Disease Stage, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球肌萎缩侧索硬化症（ALS）治疗药物市场规模为 8.6 亿美元，预计 2030 年将达到 23.1 亿美元，预测期内的复合年增长率为 12.6%。

肌萎缩侧索硬化症 (ALS) 是神经退化性疾病，其治疗药物包括多种旨在控制症状、减缓疾病进展和改善 ALS 患者生活品质的治疗方法。治疗药物可缓解肌肉无力、痉挛和疼痛等症状，提升患者的舒适度和生活品质。

根据美国疾病管制与预防中心 (CDC) 发病率和死亡率週报中发布的资料，2015美国美国发现了约 16,583 例肌萎缩侧索硬化症病例。

发病率增加

随着越来越多的患者被诊断为 ALS，对有效治疗方法的需求将会增加，从而推动研发投资。製药公司积极创新，从而引入新的治疗方法和临床试验。此外，提高对 ALS 的认识和支持将导致对研究计划的资助和支持增加。患者数量的增加，加上对疾病认识的进步，透过促进有针对性的个人化治疗方法的发展，正在推动成长。

复杂的控制途径

肌萎缩侧索硬化症 (ALS) 治疗的复杂调控途径是由于疾病的罕见性和多效性。大规模临床试验的需要，通常涉及不同的患者群体，可能会延迟药物核准。证明功效和安全性的严格要求使这一过程更加复杂。因此，新疗法上市的延迟限制了患者的治疗选择并阻碍了整体市场的成长。

越来越重视多学科治疗和支持性护理

ALS 治疗方法整合了神经病学、呼吸治疗、营养和安宁疗护，以改善患者的生活品质和治疗结果。协作护理模式促进了综合治疗计划的製定，并推动了对创新治疗和支持性干预措施的需求。此外，人们对 ALS 认识的提高以及对个人化护理的需求正在推动研究投资和伙伴关係，从而导致新型治疗方法的出现。这种整体方法提高了患者的依从性和满意度，进一步推动市场成长。

治疗费用高

治疗 ALS 的高昂费用是由于疾病的复杂性、对先进药物的需求以及持续的支持性护理。创新疗法通常供应有限，并且需要大量研发投资，从而推高了价格。这些高成本限制了患者的治疗机会，造成了经济负担，并降低了对治疗方法的依从性。这将限制患者数量并减少 ALS 药物的整体需求，影响新产品开发和市场开拓潜力并阻碍市场成长。

COVID-19 的影响

COVID-19 大流行扰乱了临床试验和研究活动，并推迟了新治疗方法的开发和核准，对 ALS 药物市场产生了重大影响。患者在取得医疗服务方面面临挑战，导致治疗方法中断并减少患者监测。此外，对 COVID-19 的关注耗尽了 ALS 研究的资源和资金。然而，大流行已经普及了远端医疗，它可以提供持续的患者支持和咨询，并可能有助于 ALS 患者的长期照护策略。

Riluzole细分预计在预测期间规模最大

预计Riluzole细分市场将在整个预测期内获得最大的市场占有率。Riluzole是 FDA认证核可药。它被归类为麸胺酸拮抗剂，透过抑制麸胺酸，谷氨酸是一种神经传导物质，过量时会导致神经细胞损伤。Riluzole已被证明可以减缓 ALS 患者的疾病进展并延长存活期，使其成为重要的治疗选择。

预计实验疗法在预测期内将经历最高的复合年增长率

预计实验治疗领域将在预测期内表现出最高的复合年增长率。透过针对疾病的潜在机制，ALS 的实验性治疗方法已显示出希望。透过专注于个人化医疗，这些实验性治疗旨在改善患者的治疗结果和生活品质。此外，我们也致力于加深对 ALS 的了解，为未来的突破铺路，并扩大 ALS 患者的治疗方法前景。

比最大的地区

由于该疾病的认识不断提高和患病率不断上升，预计亚太地区在预测期内将占据最大的市场占有率。日本、中国和印度等国家正在专注于加强有效治疗方法的研究和发展。旨在改善医疗基础设施和患者获得治疗机会的政府措施进一步支持市场扩张。此外，对支持性护理的日益重视也加强了该地区 ALS 的整体管理。

复合年增长率最高的地区：

由于先进的医疗基础设施和研发方面的大量投资，预计北美在预测期内的复合年增长率最高。美国和加拿大在创新治疗方法的临床试验方面处于领先地位，特别是基因疗法和新药物配方。大型製药公司的出现加剧了竞争，并加速了有效 ALS治疗方法的开发。此外，全面的支持性护理服务可改善患者的治疗效果和生活品质。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肌萎缩侧索硬化症（ALS）药物市场：依药物类型

  • Riluzole
  • Edaravone
  • 临床实验药物
  • 其他药物类型

第六章 全球肌萎缩侧索硬化症 (ALS) 治疗药物市场：按作用机制

  • 麸胺酸抑制剂
  • 自由基清除剂
  • 神经保护剂
  • 联合治疗
  • 其他作用机制

第七章全球肌萎缩侧索硬化症（ALS）治疗药物市场：依给药途径

  • 口服
  • 静脉
  • 皮下的
  • 肌肉注射

第八章全球肌萎缩侧索硬化症（ALS）治疗药物市场：依疾病阶段划分

  • 早期的
  • 中期
  • 晚期

第九章全球肌萎缩侧索硬化症（ALS）治疗药物市场：依应用分类

  • 症状治疗
  • 营养支持
  • 呼吸治疗
  • 物理和职业治疗
  • 实验性治疗方法
  • 补充疗法
  • 其他用途

第 10 章 全球肌萎缩侧索硬化症 (ALS) 治疗市场：依最终使用者分类

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 调查机构
  • 其他最终用户

第十一章全球肌萎缩侧索硬化症（ALS）治疗药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章 公司概况

  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Sanofi
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Orphazyme A/S
  • Regeneron Pharmaceuticals Inc.
  • Reata Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc.
  • Wave Life Sciences Limited
  • Cytokinetics Incorporated
  • NeuroSense Therapeutics Limited
  • Coya Therapeutics
Product Code: SMRC27403

According to Stratistics MRC, the Global Amyotrophic Lateral Sclerosis Therapeutics Market is accounted for $0.86 billion in 2024 and is expected to reach $2.31 billion by 2030 growing at a CAGR of 12.6% during the forecast period. Amyotrophic Lateral Sclerosis (ALS) therapeutics encompass a range of treatments aimed at managing symptoms, slowing disease progression, and improving quality of life for individuals with ALS, a neurodegenerative disorder affecting motor neurons in the brain and spinal cord. Therapeutics help alleviate symptoms such as muscle weakness, spasticity, and pain, improving patient comfort and quality of life.

According to the data published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,583 cases of amyotrophic lateral sclerosis were identified in the USA.

Market Dynamics:

Driver:

Increasing incidence rates

As more individuals are diagnosed with ALS, the demand for effective treatment options rises, driving research and development investments. Pharmaceutical companies are incentivized to innovate, leading to the introduction of novel therapies and clinical trials. Furthermore, heightened awareness and advocacy for ALS lead to increased funding and support for research initiatives. This growing patient population, coupled with advancements in understanding the disease, fuels market expansion by promoting the development of targeted and personalized treatment solutions.

Restraint:

Complex regulatory pathways

Complex regulatory pathways in Amyotrophic Lateral Sclerosis (ALS) therapeutics stem from the disease's rarity and its multifaceted nature. The need for extensive clinical trials, often involving diverse patient populations, can delay drug approvals. Stringent requirements for demonstrating efficacy and safety further complicate the process. Consequently, the slow progression of novel therapies reaching the market limits treatment options for patients and hampers overall market growth.

Opportunity:

Growing emphasis on multidisciplinary care and supportive therapies

ALS therapeutics approach integrates neurology, respiratory therapy, nutrition, and palliative care, enhancing patient quality of life and treatment outcomes. Collaborative care models promote the development of comprehensive treatment plans, driving demand for innovative therapeutics and supportive interventions. Additionally, heightened awareness of ALS and the need for personalized care encourage research investments and partnerships, leading to the emergence of novel therapies. This holistic approach fosters greater patient adherence and satisfaction, further propelling market growth.

Threat:

High treatment costs

High treatment costs in ALS therapeutics stem from the complexity of the disease, the need for advanced medications, and ongoing supportive therapies. Innovative treatments, often in limited supply, require significant research and development investment, resulting in elevated prices. These high costs can limit patient access, create financial burdens, and reduce adherence to treatment regimens. Consequently, this hampers market growth by restricting the patient population and reducing overall demand for ALS therapeutics, thus impacting the potential for new product development and market expansion.

Covid-19 Impact

The covid-19 pandemic significantly impacted the ALS therapeutics market by disrupting clinical trials and research activities, delaying the development and approval of new therapies. Patients faced challenges in accessing healthcare services, leading to interrupted treatment regimens and decreased patient monitoring. Additionally, the focus on COVID-19 diverted resources and funding away from ALS research. However, the pandemic also increased telehealth adoption, allowing for continued patient support and consultations, potentially benefiting long-term care strategies for ALS patients.

The riluzole segment is expected to be the largest during the forecast period

The riluzole segment is predicted to secure the largest market share throughout the forecast period. Riluzole is an FDA-approved drug used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It is classified as a glutamate antagonist, working primarily by inhibiting the release of glutamate, a neurotransmitter that can contribute to neuronal damage when present in excess. Riluzole is shown to slow disease progression and extend survival in ALS patients, making it a critical therapeutic option.

The experimental therapies segment is expected to have the highest CAGR during the forecast period

The experimental therapies segment is anticipated to witness the highest CAGR during the forecast period. Experimental therapies for ALS offer promising benefits by targeting the disease's underlying mechanisms. By focusing on personalized medicine, these experimental treatments aim to enhance patient outcomes and quality of life. Moreover, they contribute to a deeper understanding of ALS, paving the way for future breakthroughs and expanding the therapeutic landscape for affected individuals.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness of the disease and rising incidence rates. Countries like Japan, China, and India are focusing on enhancing research and development efforts for effective therapies. Government initiatives aimed at improving healthcare infrastructure and patient access to treatments further support market expansion. Additionally, the growing emphasis on supportive care options enhances the overall management of ALS in this region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by advanced healthcare infrastructure and significant investment in research and development. The United States and Canada are leading in clinical trials for innovative therapies, with a focus on gene therapy and novel drug formulations. The presence of major pharmaceutical companies enhances competition and accelerates the development of effective ALS therapies. Additionally, comprehensive supportive care services improve patient outcomes and quality of life.

Key players in the market

Some of the key players profiled in the Amyotrophic Lateral Sclerosis Therapeutics Market include Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Eli Lilly and Company, Amgen Inc., Sanofi, Biogen Inc., Ionis Pharmaceuticals Inc., Orphazyme A/S, Regeneron Pharmaceuticals Inc., Reata Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Wave Life Sciences Limited, Cytokinetics Incorporated, NeuroSense Therapeutics Limited and Coya Therapeutics.

Key Developments:

In August 2024, NeuroSense Therapeutics Ltd. announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.

In June 2024, Coya Therapeutics recently announced the publication of a Phase 1 clinical trial that evaluated a novel combination therapy for Amyotrophic Lateral Sclerosis (ALS) in the peer-reviewed journal Frontiers in Neurology. The study explored the effects of a combination of CTLA4-Ig and low-dose interleukin-2 (IL-2) on ALS patients.

Drug Types Covered:

  • Riluzole
  • Edaravone
  • Investigational Drugs
  • Other Drug Types

Action Mechanisms Covered:

  • Glutamate Inhibitors
  • Free Radical Scavengers
  • Neuroprotective Agents
  • Combination Therapies
  • Other Action Mechanisms

Route Of Administrations Covered:

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

Disease Stages Covered:

  • Early Stage
  • Moderate Stage
  • Advanced Stage

Applications Covered:

  • Symptomatic Treatments
  • Nutritional Support
  • Respiratory Therapies
  • Physical & Occupational Therapy
  • Experimental Therapies
  • Complementary Therapies
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Riluzole
  • 5.3 Edaravone
  • 5.4 Investigational Drugs
  • 5.5 Other Drug Types

6 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Action Mechanism

  • 6.1 Introduction
  • 6.2 Glutamate Inhibitors
  • 6.3 Free Radical Scavengers
  • 6.4 Neuroprotective Agents
  • 6.5 Combination Therapies
  • 6.6 Other Action Mechanisms

7 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Subcutaneous
  • 7.5 Intramuscular

8 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Disease Stage

  • 8.1 Introduction
  • 8.2 Early Stage
  • 8.3 Moderate Stage
  • 8.4 Advanced Stage

9 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Application

  • 9.1 Introduction
  • 9.2 Symptomatic Treatments
  • 9.3 Nutritional Support
  • 9.4 Respiratory Therapies
  • 9.5 Physical & Occupational Therapy
  • 9.6 Experimental Therapies
  • 9.7 Complementary Therapies
  • 9.8 Other Applications

10 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Homecare Settings
  • 10.5 Research Institutions
  • 10.6 Other End Users

11 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Teva Pharmaceutical Industries Limited
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 Amgen Inc.
  • 13.6 Sanofi
  • 13.7 Biogen Inc.
  • 13.8 Ionis Pharmaceuticals Inc.
  • 13.9 Orphazyme A/S
  • 13.10 Regeneron Pharmaceuticals Inc.
  • 13.11 Reata Pharmaceuticals Inc.
  • 13.12 Apellis Pharmaceuticals Inc.
  • 13.13 Wave Life Sciences Limited
  • 13.14 Cytokinetics Incorporated
  • 13.15 NeuroSense Therapeutics Limited
  • 13.16 Coya Therapeutics

List of Tables

  • Table 1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Riluzole (2022-2030) ($MN)
  • Table 4 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Edaravone (2022-2030) ($MN)
  • Table 5 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Investigational Drugs (2022-2030) ($MN)
  • Table 6 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 7 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Action Mechanism (2022-2030) ($MN)
  • Table 8 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Glutamate Inhibitors (2022-2030) ($MN)
  • Table 9 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Free Radical Scavengers (2022-2030) ($MN)
  • Table 10 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Neuroprotective Agents (2022-2030) ($MN)
  • Table 11 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Combination Therapies (2022-2030) ($MN)
  • Table 12 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Action Mechanisms (2022-2030) ($MN)
  • Table 13 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 14 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
  • Table 15 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 16 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 17 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 18 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Disease Stage (2022-2030) ($MN)
  • Table 19 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Early Stage (2022-2030) ($MN)
  • Table 20 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Moderate Stage (2022-2030) ($MN)
  • Table 21 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Advanced Stage (2022-2030) ($MN)
  • Table 22 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Application (2022-2030) ($MN)
  • Table 23 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Symptomatic Treatments (2022-2030) ($MN)
  • Table 24 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Nutritional Support (2022-2030) ($MN)
  • Table 25 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Respiratory Therapies (2022-2030) ($MN)
  • Table 26 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Physical & Occupational Therapy (2022-2030) ($MN)
  • Table 27 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Experimental Therapies (2022-2030) ($MN)
  • Table 28 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Complementary Therapies (2022-2030) ($MN)
  • Table 29 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 30 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By End User (2022-2030) ($MN)
  • Table 31 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 32 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 33 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 34 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Research Institutions (2022-2030) ($MN)
  • Table 35 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.